Third Rock Ventures LLC planted yet another seed in its garden of flourishing start-ups by forming Pliant Therapeutics Inc. with a $45 million series A designed to advance multiple small molecules and propel its lead candidate through investigational new drug (IND)-enabling studies in idiopathic pulmonary fibrosis (IPF).